BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 12595516)

  • 1. Cytomegalovirus disease after prophylaxis with oral ganciclovir in renal transplantation: the importance of HLA-DR matching.
    Schnitzler MA; Lowell JA; Hmiel SP; Hardinger KL; Liapis H; Ceriotti CS; Brennan DC
    J Am Soc Nephrol; 2003 Mar; 14(3):780-5. PubMed ID: 12595516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.
    Witzke O; Hauser IA; Bartels M; Wolf G; Wolters H; Nitschke M;
    Transplantation; 2012 Jan; 93(1):61-8. PubMed ID: 22094954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term oral ganciclovir prophylaxis for prevention of cytomegalovirus infection and disease in cytomegalovirus high-risk renal transplant recipients.
    Kletzmayr J; Kreuzwieser E; Watkins-Riedel T; Berlakovich G; Kovarik J; Klauser R
    Transplantation; 2000 Oct; 70(8):1174-80. PubMed ID: 11063336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High risk of cytomegalovirus infection following solid organ transplantation despite prophylactic therapy.
    Harvala H; Stewart C; Muller K; Burns S; Marson L; MacGilchrist A; Johannessen I
    J Med Virol; 2013 May; 85(5):893-8. PubMed ID: 23508914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 24-week oral ganciclovir prophylaxis in kidney recipients is associated with reduced symptomatic cytomegalovirus disease compared to a 12-week course.
    Doyle AM; Warburton KM; Goral S; Blumberg E; Grossman RA; Bloom RD
    Transplantation; 2006 Apr; 81(8):1106-11. PubMed ID: 16641594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation.
    Becker BN; Becker YT; Leverson GE; Simmons WD; Sollinger HW; Pirsch JD
    Am J Kidney Dis; 2002 May; 39(5):1088-95. PubMed ID: 11979354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral ganciclovir versus low-dose valganciclovir for prevention of cytomegalovirus disease in recipients of kidney and pancreas transplants.
    Weng FL; Patel AM; Wanchoo R; Brahmbhatt Y; Ribeiro K; Uknis ME; Mulgaonkar S; Mathis AS
    Transplantation; 2007 Feb; 83(3):290-6. PubMed ID: 17297403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome of low-dose ganciclovir for cytomegalovirus disease prophylaxis in renal-transplant recipients.
    Ahmed J; Velarde C; Ramos M; Ismail K; Serpa J; Ortigosa-Goggins M; Parasuraman R; Venkat KK
    Transplantation; 2004 Dec; 78(11):1689-92. PubMed ID: 15591961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir.
    Razonable RR; Rivero A; Rodriguez A; Wilson J; Daniels J; Jenkins G; Larson T; Hellinger WC; Spivey JR; Paya CV
    J Infect Dis; 2001 Dec; 184(11):1461-4. PubMed ID: 11709790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective comparison of valacyclovir and oral ganciclovir for prevention of cytomegalovirus disease in high-risk renal transplant recipients.
    Reischig T; Opatrný K; Treska V; Mares J; Jindra P; Svecová M
    Kidney Blood Press Res; 2005; 28(4):218-25. PubMed ID: 16043964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing cytomegalovirus prophylaxis in renal transplantation: single center experience.
    Varga M; Remport A; Hídvégi M; Péter A; Kóbori L; Telkes G; Fazakas J; Gerlei Z; Sárváry E; Sulyok B; Járay J
    Transpl Infect Dis; 2005 Jun; 7(2):63-7. PubMed ID: 16150092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytomegalovirus infection in renal transplant recipients: one center's experience.
    Bal Z; Uyar ME; Tutal E; Erdogan E; Colak T; Sezer S; Haberal M
    Transplant Proc; 2013; 45(10):3520-3. PubMed ID: 24314948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of donor and recipient cytomegalovirus serology on long-term survival of heart transplant recipients.
    Mabilangan C; Preiksaitis JK; Cervera C;
    Transpl Infect Dis; 2019 Feb; 21(1):e13015. PubMed ID: 30358023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Late cytomegalovirus infection after oral ganciclovir prophylaxis in renal transplant recipients.
    Murray BM; Subramaniam S
    Transpl Infect Dis; 2004 Mar; 6(1):3-9. PubMed ID: 15225220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delayed-onset primary cytomegalovirus disease after liver transplantation.
    Arthurs SK; Eid AJ; Pedersen RA; Dierkhising RA; Kremers WK; Patel R; Razonable RR
    Liver Transpl; 2007 Dec; 13(12):1703-9. PubMed ID: 18044717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparative randomised study of valacyclovir vs. oral ganciclovir for cytomegalovirus prophylaxis in renal transplant recipients.
    Pavlopoulou ID; Syriopoulou VP; Chelioti H; Daikos GL; Stamatiades D; Kostakis A; Boletis JN
    Clin Microbiol Infect; 2005 Sep; 11(9):736-43. PubMed ID: 16104989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical features and outcomes of delayed-onset primary cytomegalovirus disease in cardiac transplant recipients.
    Kijpittayarit-Arthurs S; Eid AJ; Kremers WK; Pedersen RA; Dierkhising RA; Patel R; Razonable RR
    J Heart Lung Transplant; 2007 Oct; 26(10):1019-24. PubMed ID: 17919622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Costs and outcomes of prolonged cytomegalovirus prophylaxis to cover the enhanced immunosuppression phase following lung transplantation.
    Gerbase MW; Dubois D; Rothmeier C; Spiliopoulos A; Wunderli W; Nicod LP
    Chest; 1999 Nov; 116(5):1265-72. PubMed ID: 10559085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preemptive versus sequential prophylactic-preemptive treatment regimens for cytomegalovirus in renal transplantation: comparison of treatment failure and antiviral resistance.
    van der Beek MT; Berger SP; Vossen AC; van der Blij-de Brouwer CS; Press RR; de Fijter JW; Claas EC; Kroes AC
    Transplantation; 2010 Feb; 89(3):320-6. PubMed ID: 20145523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of donor and recipient cytomegalovirus serology on long-term survival of lung transplant recipients.
    Mabilangan C; Preiksaitis J; Cervera C;
    Transpl Infect Dis; 2018 Oct; 20(5):e12964. PubMed ID: 29981174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.